Catalyst Wire Dossier Catalyst Wire Dossier

Autologous CD8+NKG2D+ AKT T-cell therapy

CD8+NKG2D+ AKT T-cell therapy
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Autologous CD8+NKG2D+ AKT T-cell therapy, covering 2016-10-11 to 2016-10-11. Get the full timeline:

Most recent: Clinical Trial Update: Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer [EARLY_Phase 1]

See pricing